Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris M Markusse

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Immunology (Orlando, Fla.)|September 21, 2017
What have we learned from BeSt?Cornelia F Allaart, Iris M Markusse, Willem F Lems
Arthritis Research & Therapy|July 3, 2015
Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'--authors' replyIris M Markusse, Willem F Lems, Tom W J Huizinga, et al.
Rheumatology (Oxford, England)|April 6, 2016
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritisIris M Markusse, Robert Landewé, Ron Wolterbeek, et al.
Arthritis Care & Research|January 13, 2015
Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?Iris M Markusse, Linda Dirven, K Huub Han, et al.
RMD Open|May 15, 2023
Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trialJoy Ardjuna van der Pol, Gülşah Akdemir, Marianne van den Broek, et al.
Arthritis Research & Therapy|September 1, 2015
Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt studyIris M Markusse, Linda Dirven, Andreas H Gerards, et al.
Clinical Rheumatology|December 24, 2015
Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritisSytske Anne Bergstra, Iris M Markusse, Gülşah Akdemir, et al.
RMD Open|June 5, 2018
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritisGülşah Akdemir, Iris M Markusse, Sytske Anne Bergstra, et al.
The Journal of Rheumatology|August 17, 2014
A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt studyIris M Markusse, Linda Dirven, Marianne van den Broek, et al.
Arthritis Research & Therapy|September 26, 2014
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisIris M Markusse, Jeska K de Vries-Bouwstra, K Huub Han, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Immunology (Orlando, Fla.)|September 21, 2017
What have we learned from BeSt?Cornelia F Allaart, Iris M Markusse, Willem F Lems
Arthritis Research & Therapy|July 3, 2015
Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'--authors' replyIris M Markusse, Willem F Lems, Tom W J Huizinga, et al.
Rheumatology (Oxford, England)|April 6, 2016
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritisIris M Markusse, Robert Landewé, Ron Wolterbeek, et al.
Arthritis Care & Research|January 13, 2015
Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?Iris M Markusse, Linda Dirven, K Huub Han, et al.
RMD Open|May 15, 2023
Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trialJoy Ardjuna van der Pol, Gülşah Akdemir, Marianne van den Broek, et al.
Arthritis Research & Therapy|September 1, 2015
Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt studyIris M Markusse, Linda Dirven, Andreas H Gerards, et al.
Clinical Rheumatology|December 24, 2015
Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritisSytske Anne Bergstra, Iris M Markusse, Gülşah Akdemir, et al.
RMD Open|June 5, 2018
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritisGülşah Akdemir, Iris M Markusse, Sytske Anne Bergstra, et al.
The Journal of Rheumatology|August 17, 2014
A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt studyIris M Markusse, Linda Dirven, Marianne van den Broek, et al.
Arthritis Research & Therapy|September 26, 2014
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisIris M Markusse, Jeska K de Vries-Bouwstra, K Huub Han, et al.
Pageof 2